ValuEngine Upgrades Genmab A/S (NASDAQ:GMAB) to Hold

Genmab A/S (NASDAQ:GMAB) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Tuesday, ValuEngine reports.

Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 target price on the stock in a research report on Thursday, September 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Genmab A/S in a research report on Wednesday, November 20th. Guggenheim started coverage on Genmab A/S in a research note on Monday, August 12th. They set a “buy” rating on the stock. Royal Bank of Canada started coverage on shares of Genmab A/S in a report on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Bank of America upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Genmab A/S currently has a consensus rating of “Buy” and an average target price of $23.67.

Shares of Genmab A/S stock traded up $0.15 on Tuesday, hitting $23.80. The company had a trading volume of 229,386 shares, compared to its average volume of 196,161. Genmab A/S has a 1 year low of $14.48 and a 1 year high of $24.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.72 and a quick ratio of 18.72. The stock’s 50 day simple moving average is $22.06. The firm has a market capitalization of $3.01 billion and a PE ratio of 6.33.

Large investors have recently bought and sold shares of the business. Private Capital Group LLC bought a new position in shares of Genmab A/S during the 2nd quarter worth approximately $41,000. Signaturefd LLC bought a new position in shares of Genmab A/S in the third quarter valued at approximately $48,000. Barclays PLC bought a new position in shares of Genmab A/S in the third quarter valued at approximately $84,000. LVW Advisors LLC purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $201,000. Finally, Moloney Securities Asset Management LLC purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $238,000. Hedge funds and other institutional investors own 19.56% of the company’s stock.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

See Also: How is the discount rate different from the Federal Funds rate?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.